LIBTAYO is indicated for the treatment of patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway...
LIBTAYO (cemiplimab) is indicated for treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC...
Summary Basis of Decision for Libtayo - Drug and Health …
Libtayo (cemiplimab) is indicated for treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Details for: LIBTAYO - Drug and Health Products Portal
Product name: LIBTAYO. Company name: REGENERON CANADA COMPANY. DIN: 02487144. Status: Marketed. Status date: 2024-06-11
Regulatory Decision Summary for Libtayo - Drug and Health …
The purpose of this New Drug Submission (NDS) was to seek market authorization for Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, for treatment of adult patients with advanced cutaneous squamous cell carcinoma.
LIBTAYO (cemiplimab for injection) is indicated for: • the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.
LIBTAYO if you have severe side effects. What is LIBTAYO? LIBTAYO is a prescription medicine used to treat: people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC). LIBTAYO may be used to treat CSCC that has …
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or...
Cemiplimab - Wikipedia
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. [7][8] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. [6][9]